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Abstract: Doxorubicin is employed alone or in combination for the treatment of several hematological
and solid malignancies; despite its efficacy, there are associated cardiotoxicity limits both in its
application in patients with heart disease risk factors and also in its long-term use. HFt-MP-PAS40 is
a genetically engineered human ferritin heavy chain (HFt)-based construct able to efficiently entrap
and deliver doxorubicin to cancer cells. HF-MP-PAS contains a short motif sequence (defined as
MP) responsive to proteolytic cleavage by tumor matrix metalloproteases (MMPs), located between
each HFt subunit and a masking polypeptide sequence rich in proline (P), alanine (A), and serine
(S) residues (PAS). This carrier displayed excellent therapeutic efficacy in a xenogenic pancreatic
cancer model in vivo, leading to a significant increase in overall animal survival in treated mice.
Herein, we describe the HFt-MP-PAS40-Dox efficacy against squamous cell carcinomas of the head
and neck (HNSCC) with the goal of validating the application of our nano-drug for the treatment
of different solid tumors. In addition, a tolerability study in healthy mice was also performed.
The results indicate that HFt-MP-PAS40-Dox produced increased anti-tumor effects both in vitro and
in vivo in comparison to the free drug in several HNSCC cell lines. In the acute toxicity studies,
the maximum tolerated dose (MTD) of HFt-MP-PAS40-Dox was about 3.5 higher than the free
drug: 25 mg/kg versus 7 mg/kg doxorubicin equivalents. Importantly, evaluation of heart tissues
provided evidence that doxorubicin is less cardio-toxic when encapsulated inside the ferritin carrier.
In conclusion, HFt-MP-PAS40-Dox may be administered safely at higher doses compared with the
free drug, resulting in superior efficacy to control HNSCC malignancies.
Keywords: pasylated ferritin; stimuli-sensitive peptides; doxorubicin; drug-delivery; head and
neck cancer
1. Introduction
Human ferritin heavy chain (HFt)-based carriers have been shown to efficiently deliver
chemotherapeutics to cancer cells [1–8]. HFt is a cage-shaped protein formed by 24 identical subunits
with external and internal diameters of 12 and 8 nm, respectively [9–15]. An important advantage of
the HFt system is the ability to be internalized by many types of tumor cells via the transferrin receptor
1 (TfR1). It was reported that a wide number of tumors express up to 100 times higher levels of TfR1
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than healthy cells and actively internalize the HFt:TfR1 ligand-receptor complex to accumulate large
amounts of iron required for the growth of cancer cells [16,17].
Recently, we have developed a novel HFt-based construct, named HFt-MP-PAS40, suitable for
drug delivery. This was dictated by the necessity of increasing both the in vivo half-life of native HFt
and the stability of HFt-drug complexes produced. This construct is characterized by an N-terminus of
each HFt subunit genetically fused to: (i) a PAS polypeptide sequence of 40 residues rich in proline (P),
alanine (A), and serine (S) residues [4,18]; and (ii) a short motif sequence (defined as MP) responsive to
proteolytic cleavage by tumor matrix metalloproteases (MMPs), inserted between each HFt subunit
and the outer PAS polypeptide. The PAS shield was used as an alternative to the less homogenous and
more expensive polyethylene glycol (PEG)-based polymers. The presence of the MP sequence allows
the PAS shield to be selectively removed by a specific stimulus present in the tumor microenvironment
so that the resulting unmasked HFt can freely be internalized by TfR1 overexpressed in tumor cells.
The HFt-MP-PAS40 construct was able to encapsulate, in the internal cavity, three times
more doxorubicin (Dox) than wild-type HFt, forming more stable complexes with higher in vivo
circulation time. Significantly, Dox-loaded HFt-MP-PAS40 (HFt-MP-PAS40-Dox) displayed excellent
antineoplastic properties in vitro towards human sarcoma and pancreatic adenocarcinoma cells, and
also human pancreatic xenotransplants in vivo [18].
The goal of the present study was to expand our preclinical studies on the HFt-MP-PAS40-Dox,
evaluating it on head and neck cancers. This type of cancer is often referred to as squamous cell
carcinomas of the head and neck (HNSCC), because it begins in the squamous cells that line the
mucosal surfaces inside the head and neck. Head and neck cancers account for approximately 4%
of all cancers in the United States [19]. The median overall survival for patients with recurrent
and/or metastatic (R/M) HNSCC remains < 1 year despite modern systemic chemotherapy and
targeted agents. Cisplatin-based chemotherapy is an important part of the multimodality treatment
for HNSCC [20,21]. However, the effectiveness of cisplatin-based monotherapy is far from being
satisfactory. In the present study, we report the use of HFt-MP-PAS40-Dox as an anticancer therapy in
a xenograft mouse model with the goal of improving the treatment of human HNSCC.
2. Results and Discussion
2.1. Dox Encapsulation in HFt-MP-PAS40
Dox encapsulation inside HFt-MP-PAS40 was achieved following the disassembly/reassembly
procedure reported previously [4]. The encapsulation efficiency using this procedure allowed about
90 molecules of Dox to be entrapped inside the protein cage, that is a value approximately three times
higher than the native HFt. This higher yield was mainly ascribed to the stabilizing effect of the PAS
polymer toward the extreme conditions required by the pH-jump used to dissociate (pH 2.0) and
re-associate (pH 8.0) the 24-mer assembly. However, to investigate if the PAS polymer may directly
interact with the Dox molecules, we decided to remove the PAS polymer after Dox encapsulation
and check it for Dox content. PAS polymer was removed using the specific matrix metalloproteases
2 and 9. After the cleavage and dialysis steps, HFt-Dox contained about 86 Dox molecules, indicating
that a negligible fraction of Dox molecules could be bound by the PAS polymer. The samples produced
were kept in sterile PBS at pH 7.4 and used for the following studies.
2.2. In Vitro Antiproliferative Effects of HFt-MP-PAS40-Dox Nanocarriers
Efficacy of HFt-MP-PAS40-Dox has been demonstrated previously in pancreatic cancer xenograft
model [18]. Herein, we decided to extend these findings to other cancers representing clear unmet
medical needs such as HNSCC. HNSCC is now the seventh most common cancer worldwide,
with a median overall survival for patients with recurrent and/or metastatic tumor remains less
than one year despite modern systemic chemotherapy and targeted agents. The HFt system has the
ability to be internalized by many types of tumor cells via the transferrin receptor 1 (TfR1). A wide
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number of tumor types (e.g., liver, lung, pancreatic, colon, cervical, ovarian, prostate and bladder,
glioblastoma, breast, sarcoma, leukemia, etc.) express high levels of TfR1. First of all, we performed
western-blot experiments to also verify the presence of this receptor on HNSCC cells of different
origin: hypopharynx (FaDu), pharynx (Detroit 562), and submaxillary salivary gland (A-253) (Figure 1).
All the HNSCC cells tested express TfR1 (Figure 1). We then assessed the killing ability of Dox-loaded
HFt-MP-PAS40 on these cell lines.
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The therapeutic efficacy of HFt-MP-PAS40-Dox was then evaluated in vivo in a model FaDu-
derived xenografts. Three million cells were inoculated subcutaneously in nude mice and when 
tumors reached an average volume of 100 mm3 animals where divided in three arms (n = 7) and 
treated with a total of five injections (twice weekly). Mock treated mice were i.v. injected with 200 μL 
of PBS; for treated mice, the injected doses were normalized to the drug (i.e., 5 mg/kg for both Dox 
or HFt-MP-PAS40-Dox). The dose used in this in vivo setting is slightly below the reported maximum 
tolerated dose for Dox (MTD: about 6–7 mg/kg) [23]. As shown in Figure 3A, while free Dox treatment 
slightly reduced tumor growth, HFt-MP-PAS40-Dox treatment resulted in significant and lasting 
Figure 1. Transferrin receptor (TfR1) expression in the human HNSCC cell lines tested. β-actin was
used as a loading control.
As shown in Figure 2, HFt-MP-PAS40-Dox was able to kill all the HNSCC cells tested in
a dose-dependent manner even better than the naked Dox. This is remarkable, since in cell
culture systems naked drugs freely diffuse into cells, whereas HFt-nanocarriers deliver the drug
Dox by rate-limiting receptor-mediated uptake. This result can be ascribed to the considerable
nuclear accumulation of the delivered drug, as revealed previously by confocal microscopy
experiments [7,18,22]. The mechanism proposed by different groups included ourselves suggest that
following TfR1 binding at cell surface, HFt-Dox carrier is internalized in an endosomal compartment
where a mildly acidic (pH 5.5) favors some Dox release/translocation in the cytoplasm, diffusion to the
nucleus, and initial DNA damage. In this way, Dox would then trigger a self-sustained, progressive
nuclear translocation loop leading to extensive cell damage. Once in the cell nucleus, HFt is degraded
releasing most of the Dox loaded. Likewise, our HFt-based canocarriers are likely to act like “Trojan
horses” delivering high amounts of the drug right to the site of action of the drug itself.
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HFt-MP-PAS40-Dox). The dose used in this in vivo setting is slightly below the reported maximum
tolerated dose for Dox (MTD: about 6–7 mg/kg) [23]. As shown in Figure 3A, while free Dox treatment
slightly reduced tumor growth, HFt-MP-PAS40-Dox treatment resulted in significant and lasting tumor
growth inhibition. Of note, at day 17 from the start of drug administration, two out of seven mice
showed nearly a complete remission (Figure 3B), resulting in a prolonged survival of 65+ days after the
start of the treatment (Figure 3C). Overall, the median survival time for HFt-MP-PAS40-Dox-treated
mice was 55 days versus 35 days for Dox and 30 days for saline control animals.
No differences in terms of body weight loss was observed in any of the treated groups (Figure 3D).
This result resembles that reported by our group using a nude mice bearing xenogeneic pancreatic
(PaCa-44) tumor model [18].
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Figure 3. Anti-tumor activity of HFt-MP-PAS40-Dox in mice bearing FaDu tumors. (A) Tumor-growth
curves for mouse groups are indicated. Student’s t-test is used to determine the statistical significance.
* p < 0.05 and ** p < 0.001; (B) Single animal tumor sizes at day 17; (C) Survival curves of different
animal groups bearing FaDu tumors. Animals were sacrificed when the tumor had reached a volume
of ≥1500 mm3. Statistical analysis was performed by Log-rank test. Control vs. Dox * p < 0.05. Control
vs. HFt-MP-PAS40-Dox ** p < 0.001. Dox vs. HFt-MP-PAS40-Dox ** p < 0.001. Arrows indicate
the five treatments (5 mg/kg Dox equivalents); (D) Body weight changes of tumor-bearing mice
after treatments.
2.4. Tolerability of HFt-MP-PAS40-Dox
To assess the Dox-associated toxicity of HFt-MP-PAS40-Dox, we performed histopathological
examination of liver and heart tissues derived from the efficacy studies. It has been reported that the
liver is the main organ for ferritin accumulation, while heart is a key tissue due to the well reported
cardiotoxicity associated to the Dox chemotherapy in clinical trials [3]. The animals of all treated
groups show no evidence of liver injuries, as evaluated by IHC (data not shown).
In the examined heart tissues, diffuse blood congestion, cytoplasmic myocyte vacuolization,
and size variation in myocyte nuclei were observed in the Dox-treated group (Figure 4B) as compared
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to the control group (Figure 4A). In contrast, only a light blood congestion phenomena were observed
for the HFt-MP-PAS40-Dox-treated group (Figure 4C).
Therefore, treatment with HFt-MP-PAS40-Dox nanocarrier can represent a promising option
for anthracycline therapeutic regimens in cardiosensitive subjects as it did not display apparent
anthracycline-related cardiotoxicity. These results well agree with those reported by other groups
using HFt-Dox as nanocarrier [3,24].Int. J. Mol. Sci. 2017, 18, 1555 5 of 8 
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Figure 4. Representative images of the histologic evaluation of heart sections of animals from the
control (A), Dox (B), and HFt-MP-PAS40-Dox (C) groups. A normal heart morphology is observed
in (A). Diffuse blood congestion (Co), cytoplasmic myocyte vacuolization (V), and size variation in
myocyte nuclei (N) are present in (B), whereas (C) shows only a light blood congestion (Co).
In addition to the histopathological experiments, a single-dose tolerability study was performed.
Healthy BALB/c mice were i.v. administered with HFt-MP-PAS40-Dox or free Dox at different mg/kg
Dox equivalents doses and monitored for body weight and signs of distress as well. The maximum
tolerated doses (MTDs) for these single injections were determined to be 7 mg/kg for Dox and
25 mg/kg for HFt-MP-PAS40-Dox. At these doses, no abnormal clinical observations or appreciable
body weight loss (less than 5%) were observed. All these results demonstrate that the encapsulation of
Dox into HFt-based nanocarriers greatly improves the drug tolerability and suggest that higher doses
than the 5 mg/kg regimen used here could be exploited for future experiments.
3. Materials and Methods
3.1. Cloning, Overexpression, and Purification of HFt- P-PAS40-Dox Construct
The recombinant protein HFt-MP-PAS40 was expressed in Escherichia coli, purified, and quantified
as previously described [18].
c e otherapeutic agent doxorubic n (DOX) (MedKoo Bioscienc s, Morrisville, NC, USA) was
encapsulated using the previously repo ted HFt disassembly/reassembly procedure (Schem 1) [4].
Briefly, soluti ns of HFt-MP-PAS40 in 0.1 M NaCl were incubated for 10 min at pH 2.5 (pH adjusted
with HCl). Then, Dox was added to the solution at 300:1 molar rati with respect to th pr tein.
The pH was initially maintained at 2.5 for 5 min and the i creased to 7.5 using NaOH. The resulting
sol tion was stirred t room temperature for 30 min, filtered a d dialyzed o.n. vs. phosphapte
buffer saline (PBS) at pH 7.4 to remove unbound Dox. After the dialysis, centrifugation and
concentration steps, protein and Dox content wer then d termined using the DOX molar extinction
coeffi ient ε = 12,250 M−1·cm−1 at 485 nm. Dox content was also evaluated fter PAS polymer removal.
Enzymatic cleavage was performed as desc ib previously using collagenase IV (Collagenase Type
4 c ntaining MMP2 and 9, Clostridium histolyticum, Abnova, Germany) [18].
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Afterwards, 72 h cell viability was inve tigated by CellTiter-Blu ® Cell Viability Assay (Promega Itali ,
Mi an, Italy) according to the manufactory inst uctions.
. . ester l t l sis
l cell lysates were pre ared using ice-cold lysis buffer supplemented with protease inhibitors.
Protein content was det rmined by Bradford method. Twenty micrograms of total proteins were l aded
on a 10% SDS-PAGE and transferred to a itrocellul se membrane. The embrane was blocked with
5% not-fat dry milk in PBS with 0.01% T een 20 for 1 h at room temperature and then incubat d
overnight with primary antibodies: anti-trasferrin (TfR1) receptor used 1:1000 (Abcam, Cambridge, UK)
and anti-β-actin use 1:40,000 (Sigma-Aldrich, Milan, Italy). T en the membrane was washed a d
incubated for 1 h at room temperature with the corresponding horseradish per xidase-c njugated
secondary antibody, diluted 1:20,000 (Bi Rad, Milan, Italy). Bound ntibodies were detected using the
enhanc d chemiluminescent (ECL) method (PerkinElmer Italia, Milan, Italy).
3.5. Therapeutic Evaluation of HFt-MP-PAS40-Dox In Vivo
Six-week-old female CD1 nude mice (Charles River Laboratories; Calco, LC, Italy) were injected
subcutaneously in the right flank with 3 × 106 FaDu cells resuspended in 200 µL of PBS. When tumors
reached a volume of about 100 mm3, mice were randomized in groups of seven animals and injected
i.v. with 200 µL of PBS, Dox or HFt-MP-PAS40-Dox. The treatment dose normalized to the Dox
concentration was 5 mg/kg. Mice were treated five times twice a week; tumor volume was measured
with a caliper and mouse weight was monitored. A tumor volume of 1500 mm3 was chosen as
endpoint after which mice were sacrificed. Survival curves were derived from Kaplan–Meier estimates
and compared by log-rank test (GraphPad Prism 5). Animal studies were performed according to
a protocol approved by the Institutional Animal Care and Use Committee of University of Verona and
authorized by the Italian Ministry of Health (Protocol No. 128/2014-B, 28/03/2014), and in accordance
with the principles laid down in the European Community Council Directives.
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3.6. Histology
When the tumor volumes exceeded 1500 mm3, animals were sacrificed. Mice heart and liver
tissues were isolated and placed into 4% formaldehyde solution (Bio-Optica, Milan, Italy) for fixation,
then dehydrated and finally embedded in paraffin. Sections were cut for hematoxylin and eosin (HE)
staining and organ toxicity analysis.
4. Conclusions
To our knowledge, this report is the first to evaluate the antitumor effects of the novel
stimuli-sensitive nano-ferritin containing doxorubicin (HFt-MP-PAS40-Dox) in any head and neck
cancer malignancy. The pharmacological activity of the drug against a panel of different HNSCC
cells was demonstrated by performing viability assays in vitro. The in vitro results showed that the
anti–HNSCC effects of HFt-MP-PAS40-Dox were comparable or even superior to the naked Dox.
Strikingly, HFt-MP-PAS40-Dox displayed excellent therapeutic efficacy in the head and neck
cancer model FaDu in vivo, reducing tumor growth and increasing animal overall survival significantly.
The higher in vivo efficacy of our nanosystem could be ascribable to the combined contribution of
active tumor targeting that exploits the selective TfR1 expression on HNSCC cells, and the increased
delivery into the cell nucleus as observed previously.
From a drug tolerability point of view, acute toxicity and histopathological studies indicate that
Dox is better tolerated when encapsulated inside the protein cavity. The maximum tolerated dose
of HFt-MP-PAS40-Dox was about 3.5 higher than the free drug and the evaluation of heart tissues
provided evidence for a safer profile of our nanosystem in terms of cardiotoxicity.
All the above findings provide support to carrying out additional preclinical studies on
HFt-MP-PAS40-Dox either as single agent, possibly at higher doses, or in combination with other
drugs in cancer therapy.
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